Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Recent Patents on Nanotechnology
  4. Volume 19, Issue 1
  5. Article
Volume 19, Issue 1
  • ISSN: 1872-2105
  • E-ISSN: 2212-4020

Abstract

Background

The molecular drug all-trans retinoic acid (ATRA) acts on cancer cells different molecular pathways, but its poor bioavailability in cancer cells limits its potency. Recently few patents have been published for the development of liposome-based drug for enhanced action. This study was, therefore, carried out to analyse the oncogene expressions in the lung tissue of benzo[a]pyrene (B[a]P)-induced mice and compare between free ATRA and cationic liposome nanoformulation (lipo-ATRA) treatments.

Objective

This study was designed to analyse the changes in the expression levels of epidermal growth factor receptor (EGFR) and B-Raf in the lung tissues of B[a]P-induced mice during the cancer development stage itself and to find the suppressive effect of free ATRA and lipo-ATRA.

Methods

Lung cancer was induced in mice by oral ingestion of 50mg/kg body weight B[a]P weekly twice for four consecutive weeks. Then, the mice were treated with free and lipo-ATRA (0.60 mg/kg) for 30 days i.v injection. The EGFR and B-Raf gene expressions were analyzed in lung cells by reverse transcriptase polymerase chain reaction (RT-PCR) and quantitative polymerase chain reaction (qPCR).

Results

The RT-PCR gene band density and the relative quantity (RQ) values from qPCR revealed both EGFR and B-Raf genes to be significantly overexpressed in B[a]P control mice while having very low or no expression in normal mice. This indicates that they function as oncogenes in B[a]P-induced lung carcinogenesis. The lipo-ATRA treatment has shown a highly significant increase in RQ values for both EGFR and BRaf when compared to the free ATRA treatment.

Conclusion

The study results have revealed the cationic lipo-ATRA treatment to have enhanced the bioavailability of ATRA in lung tissue due to its significant suppression action on EGFR-mediated oncogenes’ expressions. Furthermore, the EGFR and BRaf could be the molecular targets of ATRA action in lung carcinogenesis.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/nanotec/10.2174/0118722105246143231016105620
2023-11-01
2024-12-25

  • From This Site

    /content/journals/nanotec/10.2174/0118722105246143231016105620
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LotanR. XuX.C. LippmanS.M. Suppression of retinoic acid receptor-β in premalignant oral lesions and its up-regulation by isotretinoin.N. Engl. J. Med.1995332211405141110.1056/NEJM1995052533221037723796
     [Google Scholar]
  2. HongW.K. Retinoids and human cancer The Retinoids: Biology.2nd edChemistry and Medicine1994597630
     [Google Scholar]
  3. ChenJ. LiQ. Implication of retinoic acid receptor selective signaling in myogenic differentiation.Sci. Rep.2016611885610.1038/srep1885626830006
     [Google Scholar]
  4. BalmerJ.E. BlomhoffR. Gene expression regulation by retinoic acid.J. Lipid Res.200243111773180810.1194/jlr.R100015‑JLR20012401878
     [Google Scholar]
  5. AmannP.M. EichmüllerS.B. SchmidtJ. BazhinA.V. Regulation of gene expression by retinoids.Curr. Med. Chem.20111891405141210.2174/09298671179502961821366525
     [Google Scholar]
  6. DiSepioD. GhosnC. EckertR.L. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene.Proc. Natl. Acad. Sci.19989525148111481510.1073/pnas.95.25.148119843971
     [Google Scholar]
  7. PagliariniR. ShaoW. SellersW.R. Oncogene addiction: Pathways of therapeutic response, resistance, and road maps toward a cure.EMBO Rep.201516328029610.15252/embr.20143994925680965
     [Google Scholar]
  8. OikonomouE. KoustasE. GoulielmakiM. PintzasA. BRAF vs RAS oncogenes: Are mutations of the same pathway equal? differential signalling and therapeutic implications.Oncotarget2014523117521177710.18632/oncotarget.255525361007
     [Google Scholar]
  9. DuZ. LovlyC.M. Mechanisms of receptor tyrosine kinase activation in cancer.Mol. Cancer20181715810.1186/s12943‑018‑0782‑429455648
     [Google Scholar]
  10. KometaniT. YoshinoI. MiuraN. Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway.Cancer Lett.20092781273310.1016/j.canlet.2008.12.01719181443
     [Google Scholar]
  11. ZitoG. NaselliF. SaievaL. Retinoic acid affects lung adenocarcinoma growth by inducing differentiation via GATA6 activation and EGFR and Wnt inhibition.Sci. Rep.201771477010.1038/s41598‑017‑05047‑z28684780
     [Google Scholar]
  12. GraceB.V.M. ViswanathanS. Pharmacokinetics and therapeutic efficiency of a novel cationic liposome nano-formulated all trans retinoic acid in lung cancer mice model.J. Drug Deliv. Sci. Technol.201739223236
     [Google Scholar]
  13. RodgmanA. PerfettiT.A. The chemical components of tobacco and tobacco smoke.2nd edCRC press201623323091
     [Google Scholar]
  14. SchwartzA.G. PrysakG.M. BockC.H. CoteM.L. The molecular epidemiology of lung cancer.Carcinogenesis200628350751810.1093/carcin/bgl25317183062
     [Google Scholar]
  15. ShieldsP.G. Epidemiology of tobacco carcinogenesis.Curr. Oncol. Rep.20002325726210.1007/s11912‑000‑0076‑y11122851
     [Google Scholar]
  16. YoshinoI. KometaniT. ShojiF. Induction of epithelial-mesenchymal transition-related genes by benzo[a]pyrene in lung cancer cells.Cancer2007110236937410.1002/cncr.2272817559143
     [Google Scholar]
  17. SeshacharyuluP. PonnusamyM.P. HaridasD. JainM. GantiA.K. BatraS.K. Targeting the EGFR signaling pathway in cancer therapy.Expert Opin. Ther. Targets2012161153110.1517/14728222.2011.64861722239438
     [Google Scholar]
  18. InamuraK. NinomiyaH. IshikawaY. MatsubaraO. Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features?Arch. Pathol. Lab. Med.20101341667210.5858/2008‑0586‑RAR1.120073607
     [Google Scholar]
  19. SuzukiM. ShigematsuH. HiroshimaK. Epidermal growth factor receptor expression status in lung cancer correlates with its mutation.Hum. Pathol.200536101127113410.1016/j.humpath.2005.08.00716226114
     [Google Scholar]
  20. ShigematsuH. GazdarA.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers.Int. J. Cancer2006118225726210.1002/ijc.2149616231326
     [Google Scholar]
  21. BarrS. ThomsonS. BuckE. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.Clin. Exp. Metastasis200825668569310.1007/s10585‑007‑9121‑718236164
     [Google Scholar]
  22. BeeramM. PatnaikA. RowinskyE.K. Raf: A strategic target for therapeutic development against cancer.J. Clin. Oncol.200523276771679010.1200/JCO.2005.08.03616170185
     [Google Scholar]
  23. GuoY.J. PanW-W. LiuS-B. ShenZ-F. XuY. HuL-L. ERK/MAPK signalling pathway and tumorigenesis.Exp. Ther. Med.20201931997200732104259
     [Google Scholar]
  24. DaviesH. BignellG.R. CoxC. Mutations of the BRAF gene in human cancer.Nature2002417689294995410.1038/nature0076612068308
     [Google Scholar]
  25. WieduwiltM.J. MoasserM.M. The epidermal growth factor receptor family: Biology driving targeted therapeutics.Cell. Mol. Life Sci.200865101566158410.1007/s00018‑008‑7440‑818259690
     [Google Scholar]
  26. LynchT.J. BellD.W. SordellaR. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N. Engl. J. Med.2004350212129213910.1056/NEJMoa04093815118073
     [Google Scholar]
  27. SwinsonD.E.B. CoxG. O’ByrneK.J. Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer.Br. J. Cancer20049171301130710.1038/sj.bjc.660214915365565
     [Google Scholar]
  28. BurdickA.D. DavisJ.W.II LiuK.J. Benzo(a)pyrene quinones increase cell proliferation, generate reactive oxygen species, and transactivate the epidermal growth factor receptor in breast epithelial cells.Cancer Res.200363227825783314633709
     [Google Scholar]
  29. ZimmermannG. FurlongE.E. SuyamaK. ScottM.P. Mes2, a MADF-containing transcription factor essential for Drosophila development.Dev. Dyn.2006235123387339510.1002/dvdy.2097017029287
     [Google Scholar]
  30. PeyssonnauxC. EychèneA. The Raf/MEK/ERK pathway: New concepts of activation.Biol. Cell2001931-2536210.1016/S0248‑4900(01)01125‑X11730323
     [Google Scholar]
  31. LavoieH. TherrienM. Regulation of RAF protein kinases in ERK signalling.Nat. Rev. Mol. Cell Biol.201516528129810.1038/nrm397925907612
     [Google Scholar]
  32. NambaH. NakashimaM. HayashiT. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.J. Clin. Endocrinol. Metab.20038894393439710.1210/jc.2003‑03030512970315
     [Google Scholar]
  33. BurottoM. ChiouV.L. LeeJ.M. KohnE.C. The MAPK pathway across different malignancies: A new perspective.Cancer2014120223446345610.1002/cncr.2886424948110
     [Google Scholar]
  34. LvX. WangD. MaY. LongZ. Analysis of the oncogene BRAF mutation and the correlation of the expression of wild-type BRAF and CREB1 in endometriosis.Int. J. Mol. Med.20184131349135629286077
     [Google Scholar]
  35. AlexandrovK. RojasM. RolandoC. DNA damage by benzo(a)pyrene in human cells is increased by cigarette smoke and decreased by a filter containing rosemary extract, which lowers free radicals.Cancer Res.20066624119381194510.1158/0008‑5472.CAN‑06‑327717178892
     [Google Scholar]
  36. RamyaD. Siddikuzzaman, Grace VMB. Effect of all- trans retinoic acid (ATRA) on syndecan-1 expression and its chemoprotective effect in benzo(α)pyrene-induced lung cancer mice model.Immunopharmacol. Immunotoxicol.20123461020102710.3109/08923973.2012.69308622686587
     [Google Scholar]
  37. TariA.M. LimS.J. HungM.C. EstevaF.J. Lopez-BeresteinG. Her2/neu induces all-transretinoic acid (ATRA) resistance in breast cancer cells.Oncogene200221345224523210.1038/sj.onc.120566012149644
     [Google Scholar]
  38. CoyleKM Retinoid signaling in cancer and its promise for therapy.J Carcinog Mutag2013S7006
     [Google Scholar]
  39. SiddikuzzamanGuruvayoorappan C. Berlin Grace VM. All trans retinoic acid and cancer.Immunopharmacol. Immunotoxicol.201133224124910.3109/08923973.2010.52150720929432
     [Google Scholar]
  40. Bhat-NakshatriP. GoswamiC.P. BadveS. SledgeG.W.Jr NakshatriH. Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity.Sci. Rep.201331253010.1038/srep0253023982413
     [Google Scholar]
  41. LaineyE. WolfrommA. SukkurwalaA.Q. EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D 3 in acute myeloid leukemia cells.Cell Cycle201312182978299110.4161/cc.2601623974111
     [Google Scholar]
  42. SahJ.F. EckertR.L. ChandraratnaR.A.S. RorkeE.A. Retinoids suppress epidermal growth factor-associated cell proliferation by inhibiting epidermal growth factor receptor-dependent ERK1/2 activation.J. Biol. Chem.2002277129728973510.1074/jbc.M11089720011788593
     [Google Scholar]
  43. BastienJ. Rochette-EglyC. Nuclear retinoid receptors and the transcription of retinoid-target genes.Gene2004328111610.1016/j.gene.2003.12.00515019979
     [Google Scholar]
  44. ZhengZ.S. PolakowskaR. JohnsonA. LowellA.G. Transcriptional control of epidermal growth factor receptor by retinoic acid.Cell Growth Different: Mol Biol J Am Assoc Cancer Res199234225232
     [Google Scholar]
  45. ViswanathanS. Berlin GraceV.M. Reduced RAR-β gene expression in Benzo(a)Pyrene induced lung cancer mice is upregulated by DOTAP lipo-ATRA treatment.Gene2018668182610.1016/j.gene.2018.05.05129777906
     [Google Scholar]
  46. RamyaD. Siddikuzzaman, Manjamalai A, Berlin Grace VM. Chemoprotective effect of all-trans retinoic acid (ATRA) on oxidative stress and lung metastasis induced by benzo(a)pyrene.Immunopharmacol. Immunotoxicol.201234231732510.3109/08923973.2011.60408722066884
     [Google Scholar]
  47. RavichandranR. ViswanathanS. Berlin GraceV.M. BonatiL. NarayananJ. Ameliorating effect of lipo-ATRA treatment on the expression of TIG3 and its suppressing effect on PPARγ gene expression in lung cancer animal model.Mol. Cell. Biochem.20194601-210511210.1007/s11010‑019‑03574‑z31300983
     [Google Scholar]
  48. LiuT.X. ZhangJ.W. TaoJ. Gene expression networks underlying retinoic acid–induced differentiation of acute promyelocytic leukemia cells.Blood20009641496150410.1182/blood.V96.4.149610942397
     [Google Scholar]
  49. GiuliM.V. HaniehP.N. GiulianiE. Current trends in ATRA delivery for cancer therapy.Pharmaceutics202012870710.3390/pharmaceutics1208070732731612
     [Google Scholar]
  50. Pei Kan Ae-June Wang, Won-Ko Chen, Chih-Wan Tsao. Liposome for incorporating large amounts of hydrophobic substances.US Patent 20020058060A12002
     [Google Scholar]
/content/journals/nanotec/10.2174/0118722105246143231016105620
Loading
An Efficient Suppression of EGFR and B-Raf mRNA Overexpression in the Lung of Benzo[a]pyrene-induced mice by Cationic Lipo-ATRA Nanoformulation
Recent Pat Nanotechnol 19, 131 (2025); https://doi.org/10.2174/0118722105246143231016105620
/content/journals/nanotec/10.2174/0118722105246143231016105620
/content/journals/nanotec/10.2174/0118722105246143231016105620
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Benzo[a]pyrene; BRaf; EGFR; lipo-ATRA; lung cancer; qPCR; RT

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test